Emerging treatment strategies for breast cancer brain metastasis : from translational therapeutics to real-world experience
© The Author(s), 2020..
Systemic therapies for primary breast cancer have made great progress over the past two decades. However, oncologists confront an insidious and particularly difficult problem: in those patients with metastatic breast cancer, up to 50% of human epidermal growth factor 2 (HER2)-positive and 25-40% of triple-negative subtypes, brain metastases (BM) kill most of them. Fortunately, standard- of-care treatments for BM have improved rapidly, with a decline in whole brain radiation therapy and use of fractionated stereotactic radiosurgery as well as targeted therapies and immunotherapies. Meanwhile, advances in fundamental understanding of the basic biological processes of breast cancer BM (BCBM) have led to many novel experimental therapeutic strategies. In this review, we describe the most recent clinical treatment options and emerging experimental therapeutic strategies that have the potential to combat BCBM.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Therapeutic advances in medical oncology - 12(2020) vom: 11., Seite 1758835920936151 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ren, Ding [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Breast cancer brain metastasis |
|---|
| Anmerkungen: |
Date Revised 29.03.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1177/1758835920936151 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM312324049 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM312324049 | ||
| 003 | DE-627 | ||
| 005 | 20240329233423.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/1758835920936151 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1354.xml |
| 035 | |a (DE-627)NLM312324049 | ||
| 035 | |a (NLM)32655700 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ren, Ding |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Emerging treatment strategies for breast cancer brain metastasis |b from translational therapeutics to real-world experience |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 29.03.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s), 2020. | ||
| 520 | |a Systemic therapies for primary breast cancer have made great progress over the past two decades. However, oncologists confront an insidious and particularly difficult problem: in those patients with metastatic breast cancer, up to 50% of human epidermal growth factor 2 (HER2)-positive and 25-40% of triple-negative subtypes, brain metastases (BM) kill most of them. Fortunately, standard- of-care treatments for BM have improved rapidly, with a decline in whole brain radiation therapy and use of fractionated stereotactic radiosurgery as well as targeted therapies and immunotherapies. Meanwhile, advances in fundamental understanding of the basic biological processes of breast cancer BM (BCBM) have led to many novel experimental therapeutic strategies. In this review, we describe the most recent clinical treatment options and emerging experimental therapeutic strategies that have the potential to combat BCBM | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a breast cancer brain metastasis | |
| 650 | 4 | |a emerging treatment strategies | |
| 650 | 4 | |a translational therapeutics | |
| 700 | 1 | |a Cheng, Hao |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Vishnoi, Monika |e verfasserin |4 aut | |
| 700 | 1 | |a Teh, Bin S |e verfasserin |4 aut | |
| 700 | 1 | |a Rostomily, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Chang, Jenny |e verfasserin |4 aut | |
| 700 | 1 | |a Wong, Stephen T |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Hong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Therapeutic advances in medical oncology |d 2009 |g 12(2020) vom: 11., Seite 1758835920936151 |w (DE-627)NLM19877978X |x 1758-8340 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2020 |g day:11 |g pages:1758835920936151 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/1758835920936151 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2020 |b 11 |h 1758835920936151 | ||